Antiallergic via inhibition of chemical mediator release from mast cells. Shown to be an effective inhibitor of angiogenesis. Demonstrated to antagonize the effects of angiotensin II on human arteries, possibly by an interaction at the level of the AT1
receptor. Inhibits TRPV2-mediated responses; binds to Aβ
40 monomers and increases Aβ
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Regulation of calcium-permeable TRPV2 channel by insulin in pancreatic beta-cells.
Hisanaga et al.
Tranilast binds to Aβ monomers and promotes Aβ fibrillation.
Connors et al.
Tranilast restores cytokine-induced nitric oxide production against platelet derived growth factor in vascular smooth muscle cells.
Hishikawa et al.
Tranilast inhibits the proliferation, chemotaxis and tube formation of human microvascular endothelial cells in vitro and angiogenesis in vivo.
Isaji et al.
Tranilast, an anti-allergic drug, possesses antagonistic potency to angiotensin II.
Jin et al.